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Abstract
Background: Combined omega-3 fatty acid and vitamin D supplementation may improve multiple sclerosis (MS) by
correcting metabolic abnormalities and attenuating oxidative stress and inflammation.
Objective: This study aimed to determine the effects of ω-3 fatty acid and vitamin D cosupplementation on the disability
score and metabolic status of patients with MS.
Methods: This was a randomized, placebo-controlled clinical trial with Expanded Disability Status Scale (EDSS) score
and inflammation as primary outcomes and oxidative stress biomarkers and metabolic profile as secondary outcomes.
Patients, aged 18–55 y, were matched for disease EDSS scores, gender, medications, BMI, and age (n = 53) and
randomly received a combined 2 × 1000 mg/d ω-3 fatty acid and 50,000 IU/biweekly cholecalciferol supplement or
placebo for 12 wk. The placebos were matched in colour, shape, size, packaging, smell, and taste with supplements.
Fasting blood samples were collected at baseline and end of intervention to measure different outcomes. Multiple linear
regression models were used to assess treatment effects on outcomes adjusting for confounding variables.
Results: Patients taking ω-3 fatty acid plus vitamin D supplements showed a significant improvement in EDSS
(β −0.18; 95% CI: −0.33, −0.04; P = 0.01), compared with placebo. Serum high-sensitivity C-reactive protein
(β −1.70 mg/L; 95% CI: −2.49, −0.90 mg/L; P < 0.001), plasma total antioxidant capacity (β +55.4 mmol/L; 95%
CI: 9.2, 101.6 mmol/L; P = 0.02), total glutathione (β +51.14 µmol/L; 95% CI: 14.42, 87.87 µmol/L; P = 0.007), and
malondialdehyde concentrations (β −0.86 µmol/L; 95% CI: −1.10, −0.63 µmol/L; P < 0.001) were significantly improved
in the supplemented group comparedwith the placebo group. In addition,ω-3 fatty acid and vitamin D cosupplementation
resulted in a significant reduction in serum insulin, insulin resistance, and total/HDL-cholesterol, and a significant increase
in insulin sensitivity and serum HDL-cholesterol concentrations.
Conclusion: Overall, taking ω-3 fatty acid and vitamin D supplements for 12 wk by patients with MS had beneficial
effects on EDSS and metabolic status. This trial was registered at the Iranian website (www.irct.ir) for registration of
clinical trials as IRCT2017090133941N20. J Nutr 2018;148:1380–1386.
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Introduction
Multiple sclerosis (MS) is defined as a long-lasting inflammatory
neurodegenerative disease involving the central nervous system,
which affects young and middle-aged adults in the ages ranging
from 20 to 55 y (1). MS is evidently more common among
women with ∼60% of MS cases being female (1). Mental
illnesses such as depression might be detected in 50–60%
of patients with MS (2). Increased inflammatory markers
and oxidative damage have been suggested as a pathogenic
mechanism leading to progressiveMS (3, 4). In addition, chronic
inflammation in these patients might lead to increased insulin
resistance and postprandial hyperinsulinemia (5).
To date, the majority of clinical trials in patients with MS
have been focused on either dietary supplements like fish oil
or vitamin D (6) or specific diets such as low saturated fat,
with/without any supplement (7–10), and data on combined
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supplementation are scarce. Early studies have reported that
fish oil supplementation significantly decreased inflammatory
cytokines and nitric oxide (NO) catabolites in patients with
MS (10, 11). Previous published trials have documented that
vitamin D supplementation decreased parameters of oxidative
stress and positively influenced other metabolic profiles in these
patients (12, 13). However, in another trial of high-dose vitamin
D3 (cholecalciferol) supplementation (20,000 IU/wk) for 2 y, no
effects were examined on parameters of systemic inflammation
in patients with MS (14). In addition, fish oil supplementation
at a high dosage of 4 g/d for 12 mo did not improve oxidative
stress in patients with MS (15).
We hypothesized that combined omega-3 fatty acid and
vitamin D3 supplementation may have synergistic benefits on
the disability score, mental health, biomarkers of inflammation
and oxidative stress, and metabolic status in patients with MS.
The current study was therefore conducted to evaluate the
effects of ω-3 fatty acid and vitamin D3 cosupplementation
on disability score, biomarkers of inflammation and oxidative
stress, and metabolic profile in patients with MS.
Methods
Trial design
This study was a 12-wk randomized, double-blinded, placebo-
controlled clinical trial.
Patients
Patients in the age range of 18–55 y with relapsing-remitting MS
(RRMS) according to McDonald criteria, and an expanded disability
status scale (EDSS) score of <4.5 (16), who were referred to the Shahid
Beheshti Clinic in Kashan, Isfahan State, Iran, between November 2017
and January 2018, were included in this study. Eligible patients should
have all of the following information recorded in their documents
collected in the MS clinic: date of birth, gender, age at MS onset,
confirmed RRMS, number of relapses since the onset and delay between
the first 2 relapses, date of the measurement and EDSS scoring at that
time (or <3 mo before or after), familial antecedents of MS (defined
by the presence of 1 case in first- or second-degree relatives), and
the absence of vitamin D3 and ω-3 fatty acid supplementation before
measurement. Exclusion criteria were as follows: pregnancy or lactating
during the past 6 mo, a history of nephrolithiasis during the previous
5 y, menopause, defined as no regular menstruation, and unwillingness
to use appropriate contraception.
Ethics statements
This study followed the Declaration of Helsinki and all patients signed
the informed consent form. The research was approved by the ethics
committee of Kashan University of Medical Sciences (KAUMS) and
was registered at the Iranian website for registration of clinical trials
(http://www.irct.ir) as IRCT2017090133941N20.
Supported by a grant no.1396.64 from the Kashan University of Medical
Sciences. The financial support for conception, design, data analysis, and
manuscript drafting comes from the Research Center for Biochemistry and
Nutrition in Metabolic Diseases, Kashan University of Medical Sciences,
Kashan, Iran.
Author disclosures: EK, MA, JA, NM, FB, SAM, and ZA, no conflicts of interest.
Address correspondence to ZA (e-mail: asemi_r@yahoo.com).
Abbreviations used: EDSS, expanded disability status scale; FPG, fasting plasma
glucose; GSH, total glutathione; hs-CRP, high-sensitivity C-reactive protein; IL-
1β, interleukin-1β; IL-6, interleukin-6; MDA, malondialdehyde; METs, metabolic
equivalents; MS, multiple sclerosis; NF-кB, nuclear factor kappa B; QUICKI,
quantitative insulin sensitivity check index; RRMS, relapsing-remitting MS; TAC,
total antioxidant capacity; TNF-α, tumor necrosis factor-α.
Study design
All patients were matched for disease severity based on EDSS, gender,
type of medications, BMI, and age. They were then randomly allocated
into 2 groups to receive either 2 ω-3 fatty acid capsules daily (containing
500 mg DHA and 106 mg EPA) plus vitamin D3 as cholecalciferol
supplements (50,000 IU/biweekly) (n = 26) or sunflower oil capsules
(placebo, n = 27) for 12 wk. High-DHA fish oil capsules (7.6%
EPA + 27% DHA) and sunflower oil placebo capsules were donated by
Nu-Mega Ingredients Pty Ltd (Melbourne, Australia) and vitamin D3
capsules were manufactured by the Pharmaceutical Company (Tabriz,
Iran). The placebos were matched in colour, shape, size, packaging,
smell, and taste with the vitamin D3 and ω-3 fatty acid capsules.
The compliance rate was assessed by measuring serum 25(OH)D
(25-hydroxyvitamin D) concentrations. Intake of the ω-3 fatty acid,
vitamin D3, and placebo capsules was monitored through asking
participants to return the medication containers. To increase the
compliance rate, all patients received brief daily cellphone reminders to
take the supplements. Patients were requested to undertake their regular
physical activity and not to take any extra nutritional supplements
during the 12-wk trial. All patients completed a 3-d food record and 3
physical activity records at the baseline of the study, wk 3, 6, and 9, and
at the end of the intervention. Daily macro- and micronutrient intakes
were calculated by analyzing food records via nutritionist IV software
(First Databank, San Bruno, CA). In the current study, physical activity
was described as metabolic equivalents (METs) in h/d. To determine the
METs for each patient, we multiplied the duration of reported physical
activity (in h/d) by its relatedMETs coefficient, derived from established
standard tables (16).
Sample size
Sample size was calculated using the standard formula for clinical trials,
considering type 1 error (α) of 0.05 and type 2 error (β) of 0.20
(power = 80%). According to a previous published study (17), we used
2.65 mg/L as the difference in mean (d) and 3.30 mg/L as SD for high-
sensitivity C-reactive protein (hs-CRP) as the key variable. Based on
this information, 25 individuals were required to be included in each
treatment group. Considering 5 probable dropouts in each group, the
final sample size was determined as 30 patients in each group.
Randomization
Randomization was conducted via computer-generated random num-
bers. Randomization and allocation were concealed from the re-
searchers and patients until the final analyses were completed. The
randomized allocation sequence, enrolling patients, and allocating them
into intervention groups were performed by a trained staff at the MS
clinic.
Assessment of outcomes
The primary outcomes of this study included EDSS score and
inflammatory markers. Biomarkers of oxidative stress and metabolic
profiles were the secondary outcomes of interest in this study.
Disability score
EDSS scoring was recorded at baseline and 3 mo later, at the end of the
intervention. Patients who reported new MS symptoms in the phone
interview were invited to the clinic for further evaluation. Relapses,
which were defined as new neurologic deficits, lasting longer than 24
h, with no evidence of an infection (18), were recorded throughout
the study. All relapses were confirmed by objective neurological
examination.
Anthropometric measures
Patients’ weight and height were measured after an overnight fast, with
the use of a standard scale (Seca, Hamburg, Germany), at both the onset
of the study and after 12 wk of the trial. BMI was calculated as kg/m2.
Biomarkers
Blood samples were collected, after 12 h fasting, at the beginning and
end of the trial, at the Kashan reference laboratory. Serum 25(OH)D
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concentrations were measured with the use of an ELISA kit (IDS,
Boldon, United Kingdom) and enzyme-linked immunosorbent assay
with inter- and intra-assay CVs of <7%. Serum hs-CRP concentrations
were measured with the use of an ELISA kit (LDN, Nordhorn,
Germany) with the intra- and interassay CVs <7%. Other biomarkers
were assessed as follows: plasma NO through the use of the Giess
method (19), total antioxidant capacity (TAC) via the ferric reduction
antioxidant power method developed by Benzie and Strain (20),
glutathione (GSH) applying the Beutler et al. method (21), and
malondialdehyde (MDA) concentrations by means of the thiobarbituric
acid reactive substance method (22) with the inter- and intra-assay
CVs <5%. To measure fasting plasma glucose (FPG) and serum lipid
profiles (total cholesterol, HDL-cholesterol, LDL-cholesterol, VLDL-
cholesterol, and TGs), the study utilized the most commonly used
kits (Pars Azmun, Tehran, Iran). CVs for FPG, total cholesterol,
HDL-cholesterol, LDL-cholesterol, VLDL-cholesterol, and TGs were
1.7%, 1.6%, 1.8%, 1.9%, 2.1%, and 1.8%, respectively. Circulating
concentrations of serum insulin were assessed through the use of an
ELISA kit (Monobind, Lake Forest, CA) with the intra- and interassay
CVs<5%.The HOMA-IR and the quantitative insulin sensitivity check
index (QUICKI) were calculated according to previously established
formulas (23).
Statistical methods
Anthropometric measures and nutrient intake were compared between
intervention groups, via independent-samples t test. Multiple linear
regression models were used to assess treatment effects on the study
outcomes after adjusting for confounding variables including the
baseline values, age, and BMI. The effect sizes were presented as the
mean differences with 95% CIs. The normality of the model residual
was tested through the use of the Kolmogorov-Smirnov one-sample
test. Outcome log-transformation was applied if the model residual did
not have a normal distribution (QUICKI, TGs, and VLDL-cholesterol).
Bootstrapping was also used as a sensitivity analysis for CIs and inverse
probability weighting was used to explain loss-to-follow-up, but the
results did not change substantially. A P value of <0.05 was considered
as statistically significant. All statistical analyses were conducted via
the Statistical Package for the Social Sciences version 18 (SPSS Inc.,
Chicago, IL).
Results
At the end of the intervention, 53 patients [treatment (n = 26)
and placebo (n = 27)] completed the trial (Figure 1). Four
patients in the treatment group and 3 in the placebo group
were excluded from final analyses due to moving to another
city (n = 4) or loss of interest for participation in the research
(n = 3). Overall, the compliance rate in this study was high,
such that >90% of capsules were consumed throughout the
study in both groups. No side effects were reported after
coadministration of ω-3 fatty acid and vitamin D3 capsules in
MS patients throughout the study.
Mean age, height, weight, and BMI at baseline and end-of-
trial were not significantly different between the intervention
groups (Table 1).
Mean dietary macro- and micronutrient intakes were also
not significantly different between the 2 groups throughout the
trial (Table 2).
Our findings showed that the coadministration of ω-3 fatty
acid and vitamin D3, for 12 wk, significantly decreased EDSS
score [β (difference in the mean outcome measures between
treatment groups) −0.18; 95% CI: −0.33, −0.04; P = 0.01] in
patients with MS (Table 3). Moreover, serum hs-CRP (β −1.70
mg/L; 95% CI: −2.49, −0.90 mg/L; P < 0.001), plasma TAC
(β +55.4 mmol/L; 95% CI: 9.2, 101.6 mmol/L; P = 0.02), GSH
(β +51.14 µmol/L; 95% CI: 14.42, 87.87 µmol/L; P = 0.007),
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FIGURE 1 Summary of patient flow.
and MDA (β −0.86 µmol/L; 95% CI: −1.10, −0.63 µmol/L;
P < 0.001) improved significantly in the supplemented group,
compared with the placebo group. In addition, ω-3 fatty acid
and vitamin D3 combination resulted in a significant reduction
in serum insulin (β −2.33 μIU/mL; 95% CI: −4.03, −0.63
μIU/mL; P = 0.008), HOMA-IR (β −0.46; 95% CI: −0.83,
−0.08; P = 0.01), and total/HDL-cholesterol (β −0.43; 95%
CI: −0.85, −0.006; P = 0.04), and a significant increase in
QUICKI (β +0.01; 95% CI: 0.003, 0.02; P = 0.008) and
serum HDL-cholesterol concentrations (β +2.30 mg/dL; 95%
CI: 0.59, 4.00 mg/dL; P = 0.009) compared with the placebo.
Other biomarkers of oxidative stress, FPG, and other lipids did
TABLE 1 General characteristics of study patients1
Placebo group
(n = 27)
ω-3 fatty acid plus vitamin
D3 group (n = 26) P 2
Age, y 35.2 ± 9.2 33.3 ± 6.5 0.37
Height, cm 161.6 ± 6.4 163.2 ± 8.5 0.41
Body weight, kg
Baseline 65.1 ± 9.9 66.8 ± 11.1 0.53
Wk 12 65.0 ± 10.0 66.8 ± 11.1 0.50
Change −0.1 ± 0.7 0.1 ± 0.4 0.32
BMI, kg/m2
Baseline 24.9 ± 3.3 25.1 ± 3.9 0.83
Wk 12 24.8 ± 3.4 25.1 ± 3.9 0.78
Change −0.1 ± 0.3 0.03 ± 0.1 0.26
1Data are means ± SDs.
2Obtained from independent t test.
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TABLE 2 Dietary intakes of patients with multiple sclerosis
who were or were not supplemented with ω-3 fatty acid plus
vitamin D3 for 12 wk1
Placebo group
(n = 27)
ω-3 plus vitamin D3
group (n = 26) P 2
Energy, kcal/d 2100 ± 196 2186 ± 227 0.14
Carbohydrates, g/d 286 ± 36 297 ± 43 0.34
Protein, g/d 79 ± 20 81 ± 16 0.65
Fat, g/d 75 ± 16 79 ± 11 0.35
SFAs, g/d 24 ± 6 26 ± 4 0.37
PUFAs, g/d 23 ± 6 24 ± 6 0.49
MUFAs, g/d 21 ± 7 22 ± 5 0.55
Cholesterol, mg/d 197 ± 110 219 ± 107 0.46
ω-3 fatty acid, g/d 0.9 ± 0.4 1.0 ± 0.4 0.55
TDF, g/d 18 ± 5 19 ± 4 0.53
Vitamin D, µg/d 2.7 ± 0.7 2.9 ± 0.8 0.52
Vegetables, serving/d 3.6 ± 1.1 4.0 ± 1.0 0.26
Fruits, serving/d 2.9 ± 0.9 3.0 ± 0.8 0.54
1Values are means ± SDs. TDF, total dietary fiber.
2Obtained from independent t test.
not significantly change with ω-3 fatty acid and vitamin D3
cosupplementation.
Discussion
We evaluated the effect of coadministration of ω-3 fatty acid
and vitamin D3 at high doses, to the best of our knowledge for
the first time, on disability and metabolic status in patients with
MS. The results showed that taking ω-3 fatty acid and vitamin
D3 supplements together for 12 wk had beneficial effects on
EDSS score, serum hs-CRP, plasma TAC, GSH, MDA, insulin
metabolism, HDL-, and total/HDL-cholesterol.
Effect on clinical signs
Patients with MS are predisposed to multiple complications,
such as increased risk of cardiovascular disease, dyslipidemia
(24), insulin resistance (25), other morbidities, and an increased
mortality rate (26). Combination of ω-3 fatty acid and vitamin
D3 supplements for 12 wk led to a significant reduction in
these patients’ disabilities. Our findings were in line with other
studies showing that DHA and EPA supplementation for 2 y
resulted in a significant reduction in EDSS score in patients
with MS (27). Furthermore, it was suggested that fish oil given
together with vitamins and dietary advice could improve clinical
outcome in patients newly diagnosed with MS (27). A high-
dose vitamin D3 supplement added to routine care of pregnant
women with MS was shown to have a significant impact on
EDSS and number of relapses during pregnancy andwithin 6mo
after delivery (28). In another study, vitamin D deficiency was
significantly associated with higher risk of disability in patients
with MS (29). However, there are discrepancies among different
studies looking into the association of different nutrients with
MS. For example, Ramirez et al. (10) showed that high-dose
fish oil supplementation (4 g/d) for 12 mo did not affect EDSS
score in patients with RRMS. In a meta-analysis conducted
by James et al. (30), there was no significant relation between
high-dose vitamin D supplementation and risk of MS relapses.
The inconclusive results of different studies might be related
to their methodology including doses, administering combined
compared with individual nutrients, duration of intervention,
and other possible confounding factors. ω-3 fatty acid might
be beneficial in MS patients through immune modulation.
Its intake would reduce the synthesis of the proinflammatory
leukotriene B4 and prostaglandin E2 (31) and it can increase
the synthesis of the less inflammatory leukotriene B5 and
prostaglandin E3 (32). ω-3 fatty acid intake also would
affect the synthesis of cytokines (33), which in turn might
improve EDSS in these patients. The beneficial impacts of
vitamin D3 on mental health in patients with MS can be
explained through its role for increasing the expression of the
tyrosine hydroxylase gene and promoting the bioavailability of
some neurotransmitters such as dopamine, noradrenaline, and
adrenaline (34, 35).
Effect on biomarkers of inflammation and oxidative
stress
The cosupplementation of ω-3 fatty acid and vitamin D3
for 12 wk was found to significantly decrease inflammatory
markers including serum hs-CRP and plasmaMDA and increase
plasma total antioxidant capacity and GSH concentrations
in patients with MS. Our findings were in agreement with
other studies involving ω-3 fatty acid supplementation indi-
cating decreased production of proinflammatory markers such
as tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β),
and IL-6 (36, 37). In a meta-analysis which evaluated the
effects of fish oil supplementation in patients with chronic
heart failure, circulating inflammatory markers decreased after
3–12 mo of supplementation (38). We have previously shown
that the combination of ω-3 fatty acid and vitamin D3 for
6 wk had beneficial effects on hs-CRP, TAC, GSH, and MDA
in women with gestational diabetes (GDM) (17). Moreover,
vitamin D3 administration at a dosage of 100,000 IU monthly
for 12 wk decreased oxidative stress mediators of arterial
stiffness in overweight and obese individuals (39). On the
other hand, supplementation with 1000 mg EPA and 400 mg
DHA per d for 18 wk did not show any significant effect on
inflammatory markers like hs-CRP and IL-6 concentrations in
a healthy population (40). In another study, supplementation
with different doses of EPA plus DHA (300, 600, 900, and
1800 mg/d) for 5 mo did not change IL-6, TNF-α, and
CRP concentrations in healthy individuals (41). We also have
indicated that 50,000 IU/wk vitamin D3 supplements for 8 wk
did not influence hs-CRP concentrations, yet increased TAC and
GSH concentrations in patients with major depressive disorder
(12). Increased gene expression of peroxisome proliferator-
activated receptors by ω-3 fatty acid might inhibit the activation
of nuclear factor kappa B (NF-кB) (42), which reduces the
production of inflammatory markers. Less production of
parathyroid hormone by vitamin D supplementation (43) might
be involved in decreasing the production of inflammatory
factors including CRP. ω-3 fatty acid and vitamin D3 both
were also found to have remarkable anti-inflammatory and
antioxidant properties (44, 45). Vitamin D3 might decrease
production of reactive oxygen species and proinflammatory
cytokines (46).
Effect on glycemic control and lipid profiles
The current study demonstrated that ω-3 fatty acid and
vitamin D3 cosupplementation for 12 wk was associated
with significant improvements in glycemic control, insulin
sensitivity, and lipid profiles.We have previously shown that the
coadministration of vitamin D3 and ω-3 fatty acid to women
with GDM for 6 wk had beneficial effects on fasting glucose,
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TABLE 3 Expanded disability status scale, biomarkers of inflammation and oxidative stress, and metabolic profiles at baseline and
after the 12-wk intervention in patients with multiple sclerosis that received ω-3 fatty acid plus vitamin D3 or placebo1
Placebo group (n = 27)
ω-3 fatty acid plus vitamin D3
group (n = 26)
Difference in outcome measures between ω-3 fatty
acid plus vitamin D3 and placebo treatment groups2
Variables Baseline Wk 12 Baseline Wk 12 β (95% CI) P 3
Serum 25-hydroxyvitamin D, ng/mL 12.7 ± 2.8 13.0 ± 3.0 14.0 ± 3.1 25.2 ± 7.7 12.53 (10.49, 14.56) <0.001
EDSS 2.4 ± 0.9 2.5 ± 0.9 2.3 ± 0.6 2.2 ± 0.5 −0.18 (−0.33, −0.04) 0.01
Serum hs-CRP, mg/L 3.9 ± 2.4 4.2 ± 2.5 3.7 ± 2.0 2.6 ± 2.3 −1.70 (−2.49, −0.90) <0.001
Plasma NO, μmol/L 36.0 ± 4.0 35.2 ± 4.8 34.2 ± 3.7 34.2 ± 3.9 0.41 (−1.38, 2.21) 0.64
Plasma TAC, mol/L 1.0 ± 0.1 1.0 ± 0.1 1.1 ± 0.1 1.1 ± 0.1 55.4 (9.2, 101.6) 0.02
Plasma GSH, µmol/L 702 ± 119 698 ± 91 751 ± 89 782 ± 108 51.14 (14.42, 87.87) 0.007
Plasma MDA, µmol/L 2.8 ± 0.5 2.9 ± 0.6 3.0 ± 0.6 2.3 ± 0.5 −0.86 (−1.10, −0.63) <0.001
FPG, mg/dL 89.0 ± 8.6 90.4 ± 8.9 90.6 ± 10.3 88.9 ± 9.8 −2.28 (−5.34, 0.78) 0.14
Serum insulin, μIU/mL 12.7 ± 3.9 13.2 ± 3.8 13.4 ± 3.4 11.4 ± 3.9 −2.33 (−4.03, −0.63) 0.008
HOMA-IR 2.8 ± 0.9 2.9 ± 0.9 3.0 ± 1.0 2.5 ± 1.0 −0.46 (−0.83, −0.08) 0.01
QUICKI 0.33 ± 0.01 0.32 ± 0.01 0.32 ± 0.01 0.33 ± 0.02 0.01 (0.003, 0.02) 0.008
Serum TGs, mg/dL 133 ± 61 136 ± 58 126 ± 69 128 ± 62 −1.70 (−13.65, 10.25) 0.78
Serum VLDL-cholesterol, mg/dL 26.7 ± 12.2 27.3 ± 11.5 25.2 ± 13.7 25.6 ± 12.4 −0.34 (−2.73, 2.05) 0.78
Serum total cholesterol, mg/dL 155 ± 32 162 ± 31 159 ± 41 165 ± 40 −1.77 (−10.93, 7.39) 0.94
Serum LDL-cholesterol, mg/dL 85.0 ± 38.2 90.7 ± 37.0 89.5 ± 33.9 92.5 ± 32.3 −3.96 (−11.48, 3.55) 0.29
Serum HDL-cholesterol, mg/dL 43.3 ± 6.8 44.1 ± 6.8 44.0 ± 6.9 46.6 ± 6.6 2.30 (0.59, 4.00) 0.009
Total/HDL-cholesterol 3.7 ± 0.9 3.8 ± 0.9 3.7 ± 1.0 3.6 ± 0.9 −0.43 (−0.85, −0.006) 0.04
1Data are means ± SDs. EDSS, expanded disability status scale; FPG, fasting plasma glucose; GSH, total glutathione; hs-CRP, high-sensitivity C-reactive protein; MDA,
malondialdehyde; NO, nitric oxide; QUICKI, quantitative insulin sensitivity check index; TAC, total antioxidant capacity.
2“Outcome measures” refers to the change in values of measures of interest between baseline and wk 12. β, difference in the mean outcome measures between treatment
groups; ω-3 fatty acid plus vitamin D3 group = 1 and placebo group = 0.
3Obtained from multiple regression model (adjusted for baseline values of each biochemical variable, age, and baseline BMI).
insulin concentrations, HOMA-IR, QUICKI, TGs, and VLDL-
cholesterol concentrations (47). Supplementation with 2.4 g/d
EPA + DHA for 8 wk to hemodialysis patients also decreased
insulin concentrations and HOMA-IR (48). Von Hurst et al.
(49) determined that vitamin D supplementation at a dosage
of 4000 IU/d for 6 mo significantly improved insulin sensitivity
in healthy women. However, there was controversy regarding
the impact of vitamin D and/or ω-3 fatty acid on glycemic
control. For example, no significant difference was seen in
fasting glucose, insulin, HOMA-IR, LDL-cholesterol, leptin,
or adiponectin concentrations after the supplementation of
1800 mg/d ω-3 fatty acid for 4 mo in hemodialysis patients (50).
In another study, vitamin D supplementation with 1000 IU/d for
12 wk did not influence insulin resistance in healthy overweight
or obese women (51). Differences in the design of the studies,
lack of considering baseline values of dependent biochemical
parameters alongwith characteristics of study patients, different
dosages and types of ω-3 fatty acid and vitamin D used as
well as the duration of the intervention might provide some
reasons for discrepant findings. ω-3 fatty acid might inhibit
proinflammatory markers and suppress gene expression of NF-
кB, and so it could improve markers of insulin metabolism (52).
Vitamin D3 might as well improve glycemic control through
upregulating the insulin receptor genes (53) and increasing the
transcription of insulin receptor genes (53).
This study had a few limitations. In the present study,
we did not evaluate circulating fatty acid profiles before and
after supplementation. Further, this study did not assess gene
expression related to inflammatory cytokines and biomarkers
of oxidative stress.
In summary, the current study demonstrated that taking ω-3
fatty acid and vitamin D3 supplements together for 12 wk by
patients with MS has beneficial effects on their MS disability
score, inflammation and antioxidant capacity, and metabolic
status including insulin metabolism.
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